CADL Candel Therapeutics: חובות לטווח קצר של החברה

The price evolution of Candel Therapeutics (CADL) on the GURU.Markets platform reflects debt dynamics, which currently stand at 0.00. The business focuses on developing new tumor therapy methods. Within the framework of ESG standards, the firm is modernizing its laboratories to reduce toxic emissions and conserve energy. Additionally, the organization adheres to a basic eco-regime, minimizing paper documentation and strictly controlling the recycling of chemical waste.

For Candel Therapeutics (CADL), the short-term debt structure reflects financial stability supported by contract manufacturing organizations in the US. This indicator aggregates all obligations with a maturity of up to one year, including bank loans and accounts payable. Analyzing this trend allows for an assessment of liquidity and the risk of cash flow gaps. The reduction in debt load confirms the autonomy of the research laboratories in Massachusetts, ensuring the uninterrupted conduct of clinical drug trials.